Completed

Magnesium Sulfate Effect on Foscarnet Therapy Symptoms and Divalent Cation Levels

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Magnesium sulfate

+ Foscarnet sodium

Drug
Who is being recruted

Blood-Borne Infections+25

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+11 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
See protocol details

Summary

Principal SponsorAstra USA
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Patients are randomized to one of four treatment groups. Intravenous foscarnet is administered for 4 days. Patients receive one of three doses of magnesium sulfate or placebo in normal saline according to one of four schedules. Sequence of doses will differ for each group.

NCT00002146
Principal SponsorAstra USA
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

12 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCalcium Metabolism DisordersCommunicable DiseasesDeficiency DiseasesDNA Virus InfectionsHerpesviridae InfectionsImmunologic Deficiency SyndromesImmune System DiseasesInfectionsMetabolic DiseasesNutrition DisordersNutritional and Metabolic DiseasesRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesWater-Electrolyte ImbalanceSexually Transmitted Diseases, ViralLentivirus InfectionsMalnutritionAcquired Immunodeficiency SyndromeCytomegalovirus InfectionsHypocalcemiaMagnesium DeficiencyHIV Infections

Criteria

4 inclusion criteria required to participate
AIDS by CDC criteria

Documented CMV disease

Normal serum calcium, serum creatinine, and serum phosphate

Tolerance of foscarnet dose of 90 mg/kg bid

7 exclusion criteria prevent from participating
History of heart block

In extremis or incapacitated because of underlying illness (e.g., comatose or tracheally intubated)

Known allergy to Foscarnet

Nephrotoxic drugs such as IV pentamidine, amphotericin B, aminoglycosides, and cisplatin

Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Oklahoma City Veterans Administration Med Ctr

Oklahoma City, United StatesOpen Oklahoma City Veterans Administration Med Ctr in Google Maps
CompletedOne Study Center